Market capitalization | $64.51m |
Enterprise Value | $460.86m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.87 |
P/S ratio (TTM) P/S ratio | 0.40 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 59.00% |
Revenue (TTM) Revenue | $160.43m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Agenus Inc. forecast:
5 Analysts have issued a Agenus Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 160 160 |
59%
59%
|
|
Gross Profit | 145 145 |
80%
80%
|
|
EBITDA | -86 -86 |
58%
58%
|
EBIT (Operating Income) EBIT | -101 -101 |
53%
53%
|
Net Profit | -228 -228 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Head office | United States |
CEO | Garo Armen |
Employees | 389 |
Founded | 1994 |
Website | www.agenusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.